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Glucagon-like peptide 2 (GLP-2), a member of Glucagon peptide family involved in 
regulating energy metabolism, can be produced and secreted by preproglucagonergic 
(PPG) neurons in the brain. GLP-2 reduces food intake but at which brain sites GLP-2 
exerts its feeding-suppress effects are still unclear. In this study, we used the 
stereological microinjection technique and behavioral test to examine the functions of 
locally delivered GLP-2 into DMH on feeding behavior. We compared effects of 
different concentration of GLP-2 on the food intake behavior in free-feeding rats and 
fasted-refeeding rats. We found that GLP-2 inhibited food intake in fasted rats after a 
short-term intervention in a dose-dependent manner. Importantly, the effects of locally 
delivered GLP-2 can be blocked by specific GLP-1 receptor antagonist Exendin(9-39), 
but not the melanocortin-4 receptor antagonist SHU9119, indicating the involvement 
of specificity of GLP-2 signaling in regulating the feeding behavior. Taken together, 
our data revealed that GLP-2 peptide pharmacologically inhibited food intake in DMH 
and this effect could be blocked functionally by Exendin(9-39).  
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Gastric emptying is a critical process for the short-term control of food intake and might 
be a target for appetite modulation (Holst, 2007). Glucagon like peptide-2 (GLP-2), one 
of proglucagon-derived peptides, decreases gastric emptying (Wojdemann, et al., 1998) 
and inhibits gastric fundic tone leading to increasing gastric capacity (Amato, et al., 
2009), and therefore plays important roles in the regulation of energy absorption and 
maintenance of mucosal morphology, function and integrity of the gut (Drucker & 
Yusta, 2014). Apart from secreted from enteroendocrine L-type cells of the gut, together 
with glucagon like peptide-1 (GLP-1) in response to dietary nutrients (Holst, 2007; 
Yusta et al., 2000), GLP-2 is also released from preproglucagonergic (PPG) neurons in 
the nucleus tractus solitarius (NTS) and adjacent medial reticular nucleus of the brain 
stem (Kieffer & Habener, 1999; Vrang, et al., 2007). The brainstem preproglucagon 
neurons project predominantly rostrally with main terminal fields in hypothalamic areas 
involved in food intake regulation including the hypothalamic paraventricular (PVN), 
dorsomedial (DMH) and arcuate (Arc) nuclei (Jin et al., 1988; Larsen, et al., 1997; 
Rinaman, 1999; Vrang et al., 2007). Recent studies have revealed an intriguing 
complexity of the brainstem-hypothalamic preproglucagon system. Whereas the GLP-
1 receptor mRNA is expressed in all hypothalamic areas receiving GLP-
immunoreactive fibers (Merchenthaler, et al., 1999), the GLP-2 receptor expression in 
the hypothalamus is confined to the compact part of the DMH (Tang-Christensen, et al., 
2000).  
 
In line with the anatomical location of GLP-1 and GLP-2 receptors, it has been 
demonstrated that central administration i.e. lateral ventricular injection of either GLP-
1, GLP-2 or oxyntomodulin reduces food intake (Dakin et al., 2001; Tang-Christensen 
et al., 2000; Tang-Christensen, et al. 1998; Tang-Christensen et al., 1996; Turton et al., 
1996). However, regarding at which brain sites GLP-2 exerts its feeding-suppress 
effects are still unclear. To further address this issue, microinjection experiments by 
which GLP-2 can be administered directly into brain tissue are required.  
 
Our previous studies showed that GLP-2 microinjection into the solitary tract nucleus 
(NTS) suppressed food intake and this effect could be mediated by the GLP-1 receptor 
(unpublished data). There is a report that GLP-1 receptor antagonist, Extendin(9-39), can 
block the GLP-2 suppressed-effect on food intake through the mechanism of Exendin(9-
39) acting as a functional GLP-2 receptor antagonist (Tang-Christensen et al., 2000). In 
the present study, we discussed whether GLP-2 microinjection into DMH also has the 
feeding-suppress effects and the possible regulation mechanism of the endogenous 
melanocortin system in the DMH using the microinjection and behavioral methods in 
free-feeding and fasted-refeeding rats. 
 
Materials and Methods 
Animals 
Forty-two Sprague-Dawley (SD) adult male rats weighed 270±20g were obtained from 
the Medical Experimental Animal Center of Xi’an Jiaotong University. They were 
housed individually in cages with free access to a standard chow diet and tap water at 
25±1°C. All experiments and protocols were approved by the ethics committee, Xi’an 
Jiaotong University (No 2019-1153). All protocols followed the US National Institutes 
of Health Guide for the Care and Use of Laboratory Animals (NIH publication No. 80-
23, 1996). We randomly set up a free-feeding group and a fasted-refeeding group (10 
rats per group). Meanwhile, another two groups (11 rats per group) were set up with 
injection of the antagonists, SHU9119 and Exendin(9-39). All rats were implanted 
unilaterally guide cannulas into the DMH (details below). After the surgery, rats were 
returned to the cages for one-week habituation and recovery till their weight to reached 
270±20 g. The room lights were automatically controlled with 8:30 off and 20:30 on 
cycles for the free-feeding group, while 18:00 off and 6:00 on for the fasted-refeeding 
group. There was also an overnight 16 hours’ food deprivation (16:30-8:30) for the 
fasted-refeeding group before the start of each experiment.  
 
Stereotaxic surgery 
Rats were anesthetized with pentobarbital sodium (50mg/kg, intraperitoneally, i.p.) and 
secured on a stereotaxic apparatus (SN-2N, Narishige Group, Tokyo, Japan). The 
unilateral guide cannulas (23 gauge) were implanted into the DMH. The stereotaxic 
coordinates of the NTS were determined according to the atlas of Paxinos and Watson 
Lam (Lam et al. 2010; Walton & Paxions. 2007). The detailed settings were 0.5mm 
lateral to the midline, 2.8mm posterior to bregma, and 6.6mm ventral from the skull 
surface. The tips of the cannulas were placed 2mm above the DMH. The cannulas were 
fixed to the cranium using dental acrylic resin and jeweler screws. 30-Gauge metal 
obturators were used to fill the cannulas during the intervals of experiments between 
tests. All rats were injected with penicillin (20,000units, i.p.) during the first three post-




The experiment scheme was shown in Fig. 1. Every effort was made to reduce animal 
discomfort and the number of animals used. 
 
Fig. 1. The experiment scheme  
 
A counter-balanced experiment design (Table 1) was employed to prevent any potential 
effect from the drug dose usages and the food intake measurement time points, i.e. each 
rat received equal treatments and served as their own control subjects. Each group in 
the design experiment accepted all the same procedures but carried out in different 
orders. GLP-2, SHU9119 and Exendin(9-39) in a series of dosage and with different 
combinations were applied to test their effects on food intake on different feeding 
conditions. The free-feeding group and the fasted-refeeding group were injected into 
their DMH with three different doses of GLP-2 (1µg/0.5µl, 5µg/0.5µl, and 10µg/0.5µl) 
or vehicle (saline). In each group, 10 rats were subdivided into four subgroups of two 
or three rats each for the above four different dosage of GLP-2 injection, and each 
subgroup received these microinjections in a repeated-measures counter-balanced 
design. With this design, every rat received each dose in a non-sequential order, with a 
gap of 72h between the injections. Further experiments were designed in a similar way 
with another two groups of rats to test SHU9119 and Exendin(9-39) blocking effects on 
fasted-refeeding rats. 
 
Table 1 Experimental details of groups, drug treatments and food intake 
measurements 
 
To be specific, rats were microinjected with GLP-2, GLP-2 combined with either 
SHU9119, or Exendin(9-39) in a series of dosage. Briefly, all rats had their food removed 
Exps Feeding 
condition 
Drug  Counter-balanced  
arrangement for the dose 
Measurement 
time points for 
food intake  
1 free-
feeding 
GLP-2 0, 1, 5, 10µg 0.5, 1, 2, 3, 4, 6 
and 24hr   
2 Fasted 
refeeding 
GLP-2 0, 1, 5, 10µg 0.5, 1, 2, 3, 4, 6 






saline+GLP-2 (10µg);  
SHU9119 (0.5nmol)+saline;  
SHU 9119 (0.5nmol)+GLP-2 
(10 µg) 
0.5, 1, 2, 3, 4 







saline+GLP-2 (10µg);  
Exendin(9-39) (10µg)+saline; 
Exendin (9-39) (10µg)+GLP-2 
(10µg) 
0.5, 1, 2, 3, 4 
and 6hrs   
at 8:00. Each group received 0.5μl injection of the GLP-2 (0, 1, 5, 10 µg) into DMH at 
8:30. Rats were returned immediately to their cages after injection. Subsequent food 
intake was recorded at 0.5, 1, 2, 3, 4, 6 and 24hrs. For fasted-refeeding groups, rats have 
been fasted for 16hrs before the experiments. Each group received 0.5μl DMH injection 
of GLP-2 (0, 1, 5, 10 µg) before dark onset at 8:30. To testing the effects of SHU9119 
and Exendin(9-39) on the blocking effects on GLP-2. Each group then received 0.5μl 
DMH injections twice with fifteen minutes gaps in between with the combination of 
saline, SHU9119 (0.5nmol), and GLP-2 (10µg), or saline, Exendin(9-39) (10µg) and 
GLP-2 (10µg) at 8:30 (Table 1). Rats were then returned immediately to their cages 
after two injections. Subsequent food intake was recorded at 0.5, 1, 2, 3, 4, 6 and 24hrs. 
Delivery of the drugs  
Unilateral injections into the DMH were administered using 1µL Hamilton syringes 
(Hamilton, Reno, NV, USA) connected by PE-10 polyethylene tubing to 30-gauge 
injection cannulas. At the time of experiment, obturators were removed. The injection 
cannula (2mm longer than the guide cannula) was carefully inserted into the guide 
cannula and manual injection was initiated 15s later. The injection was delivered at a 
flow rate of 0.5µL/min for the total volume of 0.5µL. The injection cannulas were 
maintained in place for 30s after delivery of the drugs or vehicle to minimize the 
backflow. The obturators were replaced after the injections and the rats were placed 
back into their cages. 
Drugs 
GLP-2(1-33) and Exendin(9-39) (GLP-1 receptor antagonist) were purchased from Sigma 
(Sigma Chemical Company, St. Louis, MO). SHU9119 (a melanocortin receptor 
antagonist) was purchased from Tocris (Tocris Bioscience, United Kingdom). All drugs 
were dissolved in 0.9% sodium chloride immediately before the experiments. 
Accordingly, the 0.9% saline solution was used as a control vehicle. The drugs and 
vehicle solutions were prepared just before the infusion. The dose of 10µg/0.5µl 
Exendin(9-39) and 0.5nmol/0.5µl SHU9119 were chosen to test their effects on blocking 
GLP-2 inhibition on food intake according to previous studies (Guan et al., 2012; Tang-
Christensen et al., 2000).   
Measurements on food intake  
Food intake was measured by calculating the differences of the weight of the total foods 
collected immediately before the starting of the experiment and after the measurement 
time points. Any food and spilled food were recorded to the nearest 0.1g (corrected for 
spillage). Food intake measurements involving overnight food deprivation consisted of 
removing food 30minutes prior to starting deprivation and replacing the food back 
immediately after any drug microinjection or treatment. 
Verification of injections into the DMH 
To verify microinjection into the DMH was precise, at the end of the experiments, the 
rats received unilateral injections of a 0.5µl 2% Pontamine Sky Blue dye solution into 
the DMH. The rats were then given a high dose of chloral hydrate and perfused 
transcardially with saline followed by 10% buffered formalin. The brains were removed, 
fixed in 10% formalin, frozen, cut into 40µm serial coronal sections on a freezing 
microtome, and analyzed under a light microscope to exam the sites of microinjections 
in the DMH according to the atlas of Paxinos and Watson (Paxinos and Watson, 2007). 
Figure 2 showed the representative image of microinjection into the DMH after 18 days 
(7 days’ post-operative recovery and 11 days’ experiments test). 
Data Analysis 
Data were analyzed with Prism 6.0 software (GraphPad Software) and presented as the 
MEAN±SEM. Two-way RM ANOVA followed by Bonferron’s tests post hoc multiple 
comparisons were used to analyze the cumulative food intake in different groups and at 
the different measurement times. The significance value was set at p<0.05.  
 
Results 
Histological analysis of microinjections in the DMH and GLP-2 delivery into the 
DMH 
Figure 2 showed the representative image of microinjection into the DMH. Here, the 
right cannula placement showed that microinjection was correctly delivered into DMH. 
All injections were localized within DMH areas. The histological analysis showed that 
72% had unilateral injections correctly made into the DMH and the rest were outside 
DMH either too deep, in lateral or too shallow. Details for all microinjection was listed 
on Supplement Table1. Therefore, we are confident that 72 % of successful injection 
rate was still statistically satisfactory to analyze the relevant experiment data. 
 
Fig.2. Representative image of unilateral injection in the DMH. Arrow pointing to 
the injection position into DMH. DMH, dorsomedial nucleus of the hypothalamus. 3V, 
the third ventricle. Scale bar: 1mm. 
 
GLP-2 inhibits food intake in fasted-refeeding rats but not in free-feeding rats 
Firstly, we compared the cumulative food intake with different dose of GLP-2 
microinjection at different post injection time points for free-feeding rats and fasted-
refeeding rats properly in-placed. For free-feeding rats (n=7), GLP-2 had no effect on 
food intake across the measurement time points for all doses of GLP-2 used (Figure 
3A). For the fasted-refeeding rats (n=9), GLP-2 showed inhibition effects on food 
intake in a dose and time dependent manner (Figure 3B). There was no difference on 
food intake at the initial 3hrs of post-injection for all dose of GLP-2 used (Figure 3B). 
But there was significant decrease of food intake for the concentration of 10µg of GLP-
2 compared to the control at 4 h (33.1% less) and 6 h (29.7% less) post-injection (4h: 
10µg vs 0µg: 5.722±0.263g vs 8.55±1.331g, p=0.0002; 6h: 10µg vs 0µg: 7.611±0.701g 
vs 10.833±0.854g, p=0.0015, respectively), (Figure 3B). While 1µg and 5µg of GLP-2 
microinjection had no effect on food intake when compared to the control at same time 
point of measurements (4h: 1µg vs 0µg: 7.744±0.532g vs 8.55±1.331g, p>0.05; 5µg vs 
0µg: 7.867±0.864g vs 8.55±1.331g, p>0.05; 6h: 1µg vs 0µg: 9.767±0.642g vs 
10.833±0.854g, p>0.05; 5µg vs 0µg: 9.889±0.814g vs 10.833±0.854g, p>0.05, 




Fig 3. Effects on food intake with GLP-2 microinjection (0, 1, 5, and 10µg) 
unilaterally into DMH at post-injection of 0.5h, 1h, 2h, 3h, 4h, 6h and 24h for free-
feeding rats (A) (n=7) and fasted-refeeding rats (B) (n=9). *compared to 0µg of 
GLP-2, p<0.05 
 
Secondly, we compared the cumulative food intake on all rats when injections were 
mis-placed. There was no significant difference on food intake of GLP-2 with different 
dose and at different measurement time points for both free-feeding rats and the fasted-
refeeding rats (Supplement Figure1). 
 
The inhibition effect of GLP-2 on food intake in fasted-refeeding rats could be 
blocked by Exendin(9-39) but not SHU 9119  
To understand the potential mechanism of inhibition effect of GLP-2 on food intake in 
DMH, we used GLP-1 receptor antagonist, Exendin(9-39) (Tang-Christensen et al., 2000) 
and Melanocortin-4 receptor antagonist, SHU9119 (Guan et al., 2012), as central GLP-
2 receptor antagonist to test if this inhibition effect can be blocked. We used the same 
experimental design with combination of 10µg GLP-2 and Exendin(9-39) or SHU9119. 
 
Firstly, we compared the cumulative food intake at different time points on all fasted-
refeeding rats with combination of 10µg GLP-2 and SHU9119 microinjections into 
DMH properly in-placed. As expected, we found no difference on food intake at initial 
3hrs of post injection for all combination of drugs, but at 4h and 6h of post-injection, 
there were significant decrease of both food intake with 10µg of GLP-2 compared to 
the control (0µg of GLP-2), (Figure 4A). (4h: saline+GLP-2 vs saline+saline: 
5.775±0.996g vs 7.95±0.198g, p=0.0058; 6h: saline+GLP-2 vs saline+saline: 
7.4±1.251g vs 9.9±0.334g, p=0.0009). This is in line with our above results (Figure 3B), 
but this inhibition effect cannot be blocked by pre-applying SHU9119 at 4h and 6h post 
microinject measurement time point. Specifically, SHU9119 did not block GLP-2 
inhibition effect on food intake at 4h and 6h after injection (4h: saline+GLP-2 vs 
SHU+GLP-2: 5.775±0.996g vs 5.15±0.844g, p>0.05; 6h: saline+GLP-2 vs SHU+GLP-
2: 7.4±1.251g vs 6.55±1.095g, p>0.05) (Figure 4A). SHU9119 and GLP-2 combination 
decreased food intake at 4h and 6h after injection (4h: SHU+GLP-2 vs saline+saline: 
5.15±0.844g vs 7.95±0.198g, p=0.0001; SHU+GLP-2 vs SHU+saline: 5.15±0.844g vs 
8.0±0.042g, p=0.0001; 6h: SHU+GLP-2 vs saline+saline: 6.55±1.095g vs 9.9±0.334g, 
p<0.0001; SHU+GLP-2 vs SHU+saline: 6.55±1.095g vs 9.75±0.031g, p<0.0001; 
respectively) (Figure 4A). These results further confirmed that the inhibition role of 
GLP-2 on food intake in DMH in fasted-refeeding rats could not be blocked by 
SHU9119. 
 
We also test the blocking effects of Exendin(9-39) on the inhibition effect of GLP-2 in a 
parallel experiment by replacing SHU9119 with Exendin(9-39). Similarly, our data 
showed that there was no difference on food intake at initial 3hrs of post injection. But 
when we compared the cumulative food intake at 4h and 6h post-injection, there were 
significant decrease of both food intake with 10µg of GLP-2 compared to the control 
(0µg of GLP-2, at4h and 6h), (Figure 4B). (4h: saline+GLP-2 vs saline+saline: 
6.033±0.148g vs 7.567±0.542g, p=0.0379; 6h: saline+GLP-2 vs saline+saline: 
7.333±0.27g vs 9.7±0.701g, p=0.0002). This was in agreeable with the previous results 
(Figure 3B) but this inhibition effect can be nearly completely blocked by pre-applying 
Exendin(9-39). This blocking effect can be seen at 4h and 6h post microinjection 
measurement time point. (4h: Extendin(9-39) +GLP-2 vs saline+GLP-2: 7.567±0.253g vs 
6.033±0.148g, n=6, p=0.0379; Exendin(9-39)+GLP-2 vs Exendin(9-39)+saline: 
7.567±0.253g vs 7.767±0.451g, p>0.05; Exendin(9-39)+saline vs saline+GLP-2: 
7.767±0.451g vs 6.033±0.148g, p=0.0128; 6h: Extendin(9-39)+GLP-2 vs saline+GLP-2: 
10.1±0.161 vs 7.333±0.27g, p<0.0001; Exendin(9-39)+GLP-2 vs Exendin(9-39)+saline: 
10.1±0.161g vs 10.233±0.652g, p>0.05; Exendin(9-39)+saline vs saline+GLP-2: 
10.233±0.652g vs 7.333±0.27g, p<0.0001). Exendin(9-39) and the combination of 
Exendin(9-39) and GLP-2 showed no effects on food intake at all post-injection 
measurement time points compared to the control (saline+saline group, Figure 4B). 
These results further confirmed that the inhibitory role of GLP-2 on food intake could 





Fig.4. Unilaterally microinjection of SHU9119 (0.5nmol)/Exendin(9-39) (10µg) , 
respectively, into the DMH 15min prior to GLP-2 (10µg) injection. The intra-DMH 
GLP-2-induced inhibition in fasted-refeeding rats at 4 h and 6 h were not blocked 
by SHU9119 (A); however, the effects were abolished by Exendin(9-39) (B) (n=6). 
*compared to saline+saline; #compared to Exendin(9-39)+GLP-2; ^compared to 
Exendin(9-39)+saline. Values as MEAN±SEM, p<0.05. Note: Microinjection of 
SHU9119 (i.e., SHU9119+saline) (A)/Exendin(9-39) (i.e., Exendin(9-39)+saline) (B) alone 
into to the DMH had no effect on food intake as compared to saline+saline group 
(p>0.05), SHU9119+GLP-2 group/Exendin(9-39)+GLP-2 group. 
 
Above all, the fact that the inhibition effect of GLP-2 on food intake could be blocked 
by Exendin(9-39) but not SHU9119 indicated that this inhibition effect of GLP-2 on food 
intake might function through the GLP-1 receptor but not the melanocortin-4 receptor 
in DMH. Because the GLP-2 receptor antagonist has relatively high partial agonistic 
activity (Thulesen et al., 2002), and there is as yet no ideal known potent GLP-2 
receptor antagonist. GLP-1 receptor antagonist, Exendin (9-39) (Tang-Christensen et al., 
2000) and MC4-R antagonist, SHU9119 (Guan et al., 2012) were normally chosen to 
validate the blocking effect of GLP-2. 
    
Secondly, we compared the cumulative food intake at different time point on all fasted 
-refeeding rats with combination of 10µg GLP-2 and SHU9119 or Exendin(9-39)  
injections into mis-placed DMH. There was no significant difference shown in all 
groups (Supplement Figure 2). 
 
Discussion 
The roles of GLP system in the regulation of feeding behavior have been intensively 
investigated previously. However, the importance and the mechanism of action 
responsible for the GLP-2 dependent modulation of feeding remain largely uncertain 
(Tang-Christensen et al., 2000; Lovshin et al., 2001; Sørensen et al., 2003; Schmidt et 
al., 2003). It has been demonstrated that central administration i.e. lateral ventricular 
injection of either GLP-1, GLP-2 or oxyntomodulin reduces food intake (Dakin et al., 
2001; Tang-Christensen et al., 2000; Tang-Christensen, et al., 1998; Tang-Christensen 
et al., 1996; Turton et al., 1996). However, regarding at which brain sites GLP-2 exerts 
its feeding-suppress effects are still unclear. In this study, we directly administered 
microinjection of GLP-2 into brain tisuue. Our results indicated that unilaterally 
injection of GLP-2 into DMH could suppress food intake only in fasted-refeeding rats 
but not in free-feeding rats. This inhibition could be blocked by pretreatment with 
Exendin(9–39) but not SHU9119. The results from rats with misplaced injections also 
confirmed that the GLP-2 effect on food intake is specific to the DMH. 
 
The DMH is an integrative center receiving food intake related information from a 
variety of sources (Crosby, et al. 2011; Zhu, et al. 2007). GLP-2-immunoreactive fibers 
in the DMH may originate in the NTS (Vrang et al., 2007), but GLP-2 receptors are 
present predominantly in the compact not the ventral subdivision of the DMH (Tang-
Christensen et al., 2000). To our best knowledge, there is not any other study which has 
directly examined GLP-2 injection into DMH and its effect on food intake. It was 
debated that intracerebroventricular GLP-2 suppresses food intake, but peripheral GLP-
2 does not (Lovshin, et al., 2001; Tang-Christensen et al., 2000; Tang-Christensen, et 
al. 2001). Our results indicated that unilaterally injected GLP-2 into DMH could 
suppress food intake and this inhibition could be blocked by Exendin(9-39). However, in 
an in vitro assay, GLP-2 has been shown not to bind to the GLP-1 receptor, and GLP-2 
receptors are insensitive to GLP-1 (Yusta et al., 1999). While, it seems unlikely that 
Exendin(9-39) binds directly to the GLP-2 receptor and a more likely explanation is that 
GLP-1 and GLP-2 receptors act in parallel requiring both to be fully operational in order 
to induce anorexia. Glucagon-like peptide-2 actions on feeding are dependent on intact 
central GLP-1 receptors because pharmacological antagonism of GLP-1 receptors by 
prior administration of Exendin(9-39) abolishes GLP-2 induced anorexia (Tang-
Christensen et al., 2000). A pharmacological and behavioral experiment confirmed that 
this effect was via a mechanism insensitive to taste aversion (Tang-Christensen et al., 
2000). These data suggest that by activating DMH neurons a short-term reduction in 
food intake can take place. 
 
The DMH cells also express the Melanocortin-4 receptor (MC4R) (Harrold, et al., 
1999). MC4R signaling in the brain is required partially for intracerebroventricular 
GLP-2-mediated suppression of food intake and this effect in an MC4R-dependent 
manner (Guan et al., 2012). However, our results showed that SHU9119, as MC4R 
antagonist, could not block the effect of GLP-2 on food intake in DMH. We inferred 
that the reason might be due to different animals used (mice vs rat). 
 
Some studies have collectively shown that the major target of the brainstem 
preproglucagon neurons is the hypothalamus (Larsen et al., 1997; Merchenthaler et al., 
1999; Rinaman, 1999; Vrang et al., 2007). Preproglucagon projections constitute the 
predominant input from the nucleus of the solitary tract to the dorsomedial 
hypothalamic nucleus. While approximately 65% of NTS-neurons projecting to the 
DMH co-stored the preproglucagon-derived peptide GLP-2, only 25% of the NTS 
neurons projecting to the PVN were found to be GLP-ergic (Vrang et al., 2007).  
 
In this study, we examined the effects of microinjection of GLP-2 (1, 5, 10µg) into the 
DMH on food intake in free-feeding rats and fasted-refeeding rats. Unexpectedly, we 
found that GLP-2 microinjections did not significantly affect cumulative food intake in 
free-feeding rats (Figure 3A). This observation is not in agreement with previous 
reports in rodents (Rinaman et al., 1999; Lovshin et al., 2001; Tang-Christensen et al., 
2000; Dalvi et al., 2012). Tang-Christensen et al. discovered that central injection of 10 
µg of GLP-2 caused a significant decrease in 2-h food intake than vehicles in free-
feeding rats (Tang-Christensen et al., 2000). Lovshin et al. demonstrated that the central 
administration of pharmacological doses of GLP-2 powerfully inhibited short-term 
food intake in free-feeding mice (Lovshin et al., 2001). The data from Dalvi et al. also 
showed that icv 5 µg of GLP-2 remarkably suppressed food intake in free-feeding mice 
(Dalvi et al., 2012). It is somewhat difficult to explain the discrepancy of their results 
with ours from the free-fed animals. The difference might be due to the administration 
route (icv vs intra-DMH.) and, subsequently, different sites of action of the GLP-2. 
Notably, all three studies mentioned above-injected GLP-2 into either the lateral 
ventricle or the third cerebral ventricle to focus on the interactions of GLP-2 with the 
major hypothalamic nuclei that lie in the vicinity of the third or lateral ventricle. 
However, our data derived from the anorexigenic action of GLP-2 was injected directly 
into the DMH.    
 
It is worth noting that the expression of appetite regulatory peptides/hormones is known 
to be changed by fasting or food deprivation (Yuan et al., 2014). Thus, the condition 
that influences of anorectic or orexigenic hormones and nutritional signals can be 
reduced or increased, respectively. In the present study, the anorectic effect was only 
detected in the fasted rats suggesting that the effect of intra-DMH injection of GLP-2 
may be related to the nutritional state of animals.  
 
Our results showed the reduction of food intake observed four-six hours after the 
injection instead in the first hours (Baldassano et al., 2012) and 2-hours (Tang-
Christensen et al., 2000). The reason for this could be complex as mentioned above. 
These might due to different animal species (C57BL/J mice, Wistar rats,), different 
route of GLP-2 application (i.p. centrially administered, lateral ventricle ICV), and 
other conditions. In this study, we used SD rats, GLP-2 injected directly into DMH. 
However, similar observation was also observed where the reduction of food intake 
observed from first-four hours after an intracerebroventricular injection of h[Gly2] 
GLP-2 into in mice (Lovshin et al., 2001). Further investigation is therefore needed to 
investigate how these differences occur. 
 
In conclusion, our study indicated that GLP-2 pharmacologically inhibited food intake 
in DMH and this effect could be blocked functionally by Exendin(9-39). This was the 
first study on the effect of direct administration of GLP-2 and its antagonist in the 
medial hypothalamic nucleus on feeding behavior, and preliminarily explained the 
interaction between GLP-2 and the dorsal medial hypothalamic nucleus. Our results 
would provide useful information on the regulation mechanism of food intake and may 
provide a new target for the treatment of obese patients. 
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Supplement Table 1 Microinjection in DMH 
number of animals microinjected in 
DMH in place 
microinjection 
outside the DMH 
free-feeding group, n = 10 n = 7 n = 3 
fasted-refeeding group, n = 10 n = 9 n = 1 
for SHU9119 experiments, n = 11,  
3 died during the experiment 
n = 6 n = 2 
for Exendin(9-39) experiments, n = 11 n = 6 n = 5 
 
 
Supplement Figure 1. Microinjection of GLP-2 (0, 1, 5, and 10µg) unilaterally 
outside DMH effects on food intake at 0.5h, 1h, 2h, 3h, 4h, 6h and 24h after 
injection in free-feeding rats (A) (n=3) and fasted-refeeding rats (B) (n=1). No 







Supplement Figure 2. Microinjection of GLP-2 (10µg) unilaterally outside DMH 
had no effect on food intake at 4h to 6h after injection in fasted-refeeding rats. 
SHU9119 (0.5nmol) (n=2) (A) Exendin(9-39) (10µg) (n=5) (B). Cumulative food intake 
was recorded at 0.5h, 1h, 2h, 3h, 4h, and 6h after injection. *compared to saline+saline; 
#compared to Exendin(9-39)+GLP-2; ^compared to Exendin(9-39)+saline. Values as 
Mean± S.E.M., p<0.05 
 
 
 
 
 
